SciSparc Ltd. SPRC

SciSparc announces that NeuroThera, in collaboration with Clearmind, expanded its US patent portfolio with three new patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines (including palmitoylethanolamide, PEA) for potential CNS and mental health indications such as depression, PTSD, pain and substance-use disorders. The filings build on prior IP, including MDMA/PEA combinations, and aim to support development of safer, effective therapies using NeuroThera's PEA technology, while SciSparc also references other programs like SCI-110 and SCI-210 and notes forward-looking statements and standard risk disclosures. Expands NeuroThera/Clearmind patent portfolio with psychedelic combos, signaling potential future therapies but with speculative commercialization.

SciSparc subsidiary NeuroThera Labs seeks FDA Orphan Drug Designation for adult Tourette Syndrome treatment and engages RK Strategies for government and public affairs. Orphan drug designation pursuit for Tourette syndrome drug may enhance development opportunities and regulatory advantages for SciSparc.

SciSparc subsidiary NeuroThera Labs seeks FDA Orphan Drug Designation for adult Tourette Syndrome drug and engages RK Strategies for government and public affairs. Subsidiary FDA orphan drug pursuit and firm engagement indicate moderate regulatory progress for Tourette syndrome treatment.

NeuroThera Labs achieves significant enrollment momentum in SCI210 Autism Clinical Trial for SciSparc Ltd. (SPRC). Enrollment progress in SCI210 autism trial advances SciSparc's key pipeline asset and investor outlook.

SciSparc subsidiary NeuroThera Labs reports significant enrollment momentum in its SCI-210 clinical trial for autism. Trial enrollment progress advances subsidiary's autism drug development program.

SciSparc Ltd. adds Prof. Carmel Domshlak, an internationally recognized AI expert, to its Scientific Advisory Board to advance the company's Agentic AI strategy. Advisory board appointment strengthens AI expertise but represents incremental rather than transformative progress for operations or market position.

SciSparc advances MDMA-N-acylethanolamines IP via NeuroThera-Clearmind collaboration for PTSD treatment amid rising U.S. federal support for psychedelic therapies. NeuroThera-Clearmind IP advancement strengthens SciSparc PTSD pipeline with new combination therapy amid expanding federal psychedelic funding.

SciSparc Ltd. subsidiary NeuroThera Labs completed C$5.4 million financing, with SciSparc's stake valued at approximately C$30 million. Subsidiary financing success at high valuation directly strengthens SciSparc financial position and growth outlook.

NeuroThera Labs received a Japanese patent for its proprietary therapeutic combination, bolstering SciSparc Ltd. intellectual property position in Japan. Japanese patent grant adds targeted IP protection that may support future product positioning but does not immediately shift company trajectory.

NeuroThera Labs launches Phase IIb clinical trial at Yale Child Study Center for first-of-its-kind Tourette Syndrome treatment. Phase IIb trial start for novel Tourette therapy at major center signals major strategic progress with potential to shift company trajectory.

SciSparc subsidiary NeuroThera Labs launches Phase IIb clinical trial at Yale Child Study Center for first-of-its-kind Tourette Syndrome treatment. Phase IIb trial launch for Tourette treatment advances SciSparc pipeline and market prospects substantially.

SciSparc subsidiary NeuroThera Labs demonstrated a complete end-to-end hybrid quantum-classical workflow for clinical data analytics via its Quantum Platform. NeuroThera Labs quantum workflow demonstration signals emerging technological capabilities that could influence SciSparc positioning in data analytics.

SciSparc advances quantum clinical data analytics as NeuroThera validates proprietary computing platform. Quantum analytics advance and platform validation signal major strategic progress for SciSparc.

SciSparc subsidiary NeuroThera Labs advances its quantum platform for clinical data analytics on an S&P 500 company's platform. Subsidiary quantum platform advancement may improve data analytics capabilities and support modest gains in company positioning.

SciSparc Ltd. decides to target the agentic AI market and forms a scientific advisory board for artificial intelligence and cybersecurity. Entry into agentic AI market via new advisory board marks major strategic shift with potential to alter company trajectory and investor sentiment.

NeuroThera Labs begins Phase IIb clinical trial at Hannover Medical School in Germany testing new Tourette Syndrome treatment. Phase IIb trial initiation marks major clinical milestone that can shift company trajectory and investor sentiment.

SciSparc subsidiary NeuroThera Labs begins Phase IIb clinical trial at Hannover Medical School in Germany for Tourette Syndrome treatment. Phase IIb trial start marks major clinical development milestone for core Tourette Syndrome program.

SciSparc Ltd.'s subsidiary NeuroThera Labs received conditional regulatory approval to acquire CliniQuantum. Conditional approval advances subsidiary acquisition that may moderately expand company operations.

SciSparc announces collaboration between NeuroThera Labs and Clearmind Medicine leading to patent application for innovative depression therapy. Patent application from strategic collaboration advances depression therapy pipeline, enhancing competitive positioning and market potential.

NeuroThera Labs, linked to SciSparc Ltd. (SPRC), collaborates with Clearmind Medicine to file a patent application for a novel depression therapy. Patent application from collaboration expands SPRC's therapeutic pipeline and enhances competitive positioning in mental health treatments.

NeuroThera Labs announces publication of an international patent in collaboration with Clearmind Medicine for a novel therapy targeting weight loss and fatty liver disease. International patent publication for obesity and liver disease therapy bolsters SciSparc's innovation pipeline and investor appeal in high-demand therapeutic areas.

NeuroThera Labs, in collaboration with Clearmind Medicine, announced the publication of an international patent for a novel therapy targeting weight loss and fatty liver disease. International patent publication for a novel therapy in weight loss and fatty liver disease bolsters SciSparc's product pipeline through its NeuroThera Labs collaboration.

SciSparc Ltd.'s 75%-owned subsidiary NeuroThera Labs signed a definitive agreement to acquire a majority stake in CliniQuantum, an innovator in quantum-based clinical trials. Acquiring a majority stake in a quantum-based clinical trials innovator enables major strategic expansion into cutting-edge technology that could accelerate SciSparc's drug development and enhance competitive positioning.

NeuroThera Labs has been granted a U.S. patent for its cannabinoid technology aimed at combating antimicrobial resistance, including strains like MRSA. This innovation could potentially enhance treatment options and address significant public health challenges related to antibiotic resistance. The patent could lead to significant advancements in treatment options, impacting SciSparc's strategic positioning and market sentiment.

Neurothera Labs has been granted a U.S. patent for its cannabinoid technology aimed at combating antimicrobial resistance, including strains like MRSA. This innovation could provide new treatment options in the fight against antibiotic-resistant infections, highlighting the potential of cannabinoids in medical applications. The patent could significantly enhance SciSparc Ltd.'s product offerings and market position in the growing field of antimicrobial treatments.

SciSparc Ltd. has successfully completed the acquisition of an intellectual property portfolio, which positions the company for immediate commercialization of its products. This strategic move is expected to enhance its market presence and drive future growth. The acquisition of the IP portfolio is a significant strategic move that could alter the company's trajectory and investor sentiment.

SciSparc Ltd. has signed a definitive agreement to acquire a treasury of patents related to the endoscope market, positioning the company to enter a multi-billion dollar opportunity. This strategic move aims to enhance its product offerings and capitalize on the growing demand in the medical technology sector. Acquiring patents in the endoscope market represents a significant strategic move that could enhance product innovation and market positioning.

SciSparc Ltd. (SPRC) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and interest among investors. The company's recent developments and market positioning have contributed to its visibility, attracting attention from traders and analysts alike. This increased activity may indicate potential shifts in investor sentiment or market dynamics surrounding the company. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

SciSparc Ltd. (SPRC) has received a notification from Nasdaq regarding its non-compliance with the minimum stockholders' equity requirement. The company is currently evaluating its options to regain compliance, which may include potential financing or restructuring efforts. This notification highlights ongoing financial challenges faced by SciSparc as it seeks to maintain its listing on the Nasdaq exchange. Non-compliance with Nasdaq's requirements may affect investor sentiment and financial performance but does not fundamentally alter the company's trajectory.

Neurothera Labs has been granted a patent by the Israeli Patent Office for its proprietary opioid-based patent family aimed at enhancing pain relief while reducing side effects. This development is expected to advance SciSparc Ltd.'s position in the pain management sector, potentially leading to innovative treatment options. The patent grant represents a significant strategic move that could enhance product offerings and market positioning in the pain relief sector.